1 / 33

Progressive Neurologic Disease in Immunosuppressed Patients

Progressive Neurologic Disease in Immunosuppressed Patients. Clinical Grand Rounds Edward L. Goodman, MD, FACP November 16, 2005. Case Presentation #1.

parson
Download Presentation

Progressive Neurologic Disease in Immunosuppressed Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Progressive Neurologic Disease in Immunosuppressed Patients Clinical Grand Rounds Edward L. Goodman, MD, FACP November 16, 2005

  2. Case Presentation #1 • 66 year old man 19 years s/p LRD renal transplant admitted with left sided weakness. Also has alcoholic cirrhosis, IDDM, CAD, cholelithiasis, bilateral THR. • Two months earlier MRI revealed white matter lesions. • Meds include NPH and Insulin lispro, azathioprine, prednisone, pantoprazole, B12, folic acid, B6, C vit, gabapentin, quetiapine, spirinolactone, lactulose, lorazepam. • Exam revealed mild left hemiparesis. • Labs were non revealing. • Brain biopsy diagnostic • Expired a few months later.

  3. MRI Scan Obtained Two Months before the First Hospital Admission Koralnik, I. J. et al. N Engl J Med 2004;350:1882-1893

  4. MRI Study Showing Progression of the Lesion over Time Koralnik, I. J. et al. N Engl J Med 2004;350:1882-1893

  5. Specimen from a Stereotactic Brain Biopsy Koralnik, I. J. et al. N Engl J Med 2004;350:1882-1893

  6. Identification of Polyomavirus JC in a Biopsy Specimen of the Brain Koralnik, I. J. et al. N Engl J Med 2004;350:1882-1893

  7. Case #2 • 41 yo woman with MS 1999 treated with interferon, methylprednisone and finally Natalizumab. • November 2004 new and different CNS symptoms developed. Work up failed to reveal an etiology. • Just prior to death, CSF sent for PCR for JC virus was positive.

  8. Doses and Timing of Treatments for Multiple Sclerosis Kleinschmidt-DeMasters, B. et al. N Engl J Med 2005;353:369-374

  9. MRI Findings (Panels A, B, and C) and Autopsy Findings (Panel D) Kleinschmidt-DeMasters, B. et al. N Engl J Med 2005;353:369-374

  10. Histologic and MRI Findings Kleinschmidt-DeMasters, B. et al. N Engl J Med 2005;353:369-374

  11. Case #3 • 60 yo man with Crohn’s became confused while on Natalizumab. • CT showed nonenhancing hypodense lesions in white matter of right frontal lobe, left frontal and right temporal lobes. • Brain biopsy performed • Died three months later

  12. Peripheral-Blood Neutrophil and Lymphocyte Counts in Relation to Natalizumab Therapy Van Assche, G. et al. N Engl J Med 2005;353:362-368

  13. Initial MRI Findings Van Assche, G. et al. N Engl J Med 2005;353:362-368

  14. Histologic Findings Van Assche, G. et al. N Engl J Med 2005;353:362-368

  15. Time Course of JC Viral Load in Serum and Brain Van Assche, G. et al. N Engl J Med 2005;353:362-368

  16. Causes of Leukoencephalopathy in Adults Koralnik, I. J. et al. N Engl J Med 2004;350:1882-1893

  17. Polyomaviruses • Small, non enveloped virus, 42 nm • Circular double stranded DNA, 5000 bp • Two human species, one animal • BK virus • 50% seroprevalence by 3-4 years • 100% by 10-11 years • JC virus • 80% prevalence in adults • SV40 contaminated inactivated poliovirus vaccine 1955-61

  18. Pathophysiology • Site of entry unknown -?tonsils • Latency in kidneys/bone marrow/lymphatics • Periodically reactivate • Shed in urine • With immunosuppression • Hematogenous spread to brain • Infects oligodendrocytes • Leads to demyelination

  19. Management Issues • PML has been described in up to 5% of AIDS patients • This represents a large pool from which to study natural history and treatment • Berenguer et al. Clinical Course and Prognostic Features of PML in Patients Treated with HAART. CID 2003;36: 1047-52

  20. Anti-viral therapy • No evidence of benefit in AIDS patients with • Topothecan (Royal et al. J Neurobiology 2003;9:411-419) • Cidofovir (Marra CM et al. A pilot study of cidofovir for PML in AIDS. AIDS 2002;16:1791-1797) • IFN-alfa2B (Geschwind et al.J Neurobiology 2001;7:375-381 • Cytosine arabinoside (Hall et al N Eng J Med 1998;338:1345-1351) • Non AIDS patients • One retrospective study on Cytosine arabinoside stabilized PML in 7/19 (Aksamit AJ. J Neurovirol 2001;7:386-390)

  21. What can we learn from the Natalizumab experience? • Monoclonal antibody against α4 integrin • Inhibits binding of cells expressing α4β1 and α4β7 integrins to adhesion molecules on endothelium • Limiting diapedesis of lymphocytes into organs, the proposed mechanism for • MS • Crohn’s

  22. Natalizumab cont’d • But JC virus thought to be carried to CNS by lymphocytes, so • Inhibiting lymphocyte entry into CNS shouldn’t precipitate PML, unless • Other means of JC getting into CNS • Cell free virus, or • Was JC virus latent already in CNS?

  23. Conclusion • Consider PML in immunosuppressed patients with • Progressive mulifocal neurologic disease • Non enhancing white matter disease on MRI • Send CSF for JC virus DNA by PCR • Try and halt immunosuppression or improve immune status • e.g, HAART in AIDS patients • Halting immunomodulatory therapy in Crohn’s or MS

  24. Bibliography • Berger JR, Koralnik IJ. Progressive Multifocal Leukoencephalopathy and Natalizumab- Unforseen Consequences. N Eng J Med 2005;353:414-416 • Berenguer J, Miralles P et al. Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral Therapy. Clinical Infectious Diseases 2003;36:1047-1052 • Kleinschmidt-DeMasters BK, Tyler KL. Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis. New Eng J Med 2005;353:369-374

  25. Bibliography continued • Koralnik IJ, Schellingerhout D and Frosch MP. Cases 14-2004: A 66 Year-Old Man with Progressive Neurologic Deficits. N Eng J Med 2004;350;1882-1893. • Koralnik IJ. New insights into progressive multifocal leucoencephalopathy. Current Opinion in Neurology 2004; 17:365-370. • Langer-Gould A, Atlas SW et al. Progressive Multifocal Leukocncephalopathy in a Patient Treated with Natalizumab. N Eng J Med 2005;353:375-381 • Sabath BF, Major EO. Traffice of JC Virus from Sites of Initial Infection to the Brain:The Path to Progressive Multifocal Leukoencephalopathy. J Inf Dis 2002; 186(Suppl2):S180-186 • Von Assche G, Van Ranst M et al. Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn’s Disease. N Eng J Med 2005;353:362-368

More Related